We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Proteomic Test Stratifies Patients for Immunotherapies

By LabMedica International staff writers
Posted on 28 Dec 2016
Print article
Image: Sample application for the VeriStrat proteomic serum test for advanced non-small-cell lung cancer which helps physicians determine whether a patient should receive treatment with an epidermal growth factor receptor inhibitor (Photo courtesy of Biodesix).
Image: Sample application for the VeriStrat proteomic serum test for advanced non-small-cell lung cancer which helps physicians determine whether a patient should receive treatment with an epidermal growth factor receptor inhibitor (Photo courtesy of Biodesix).
Anti PD-1 inhibitors are the treatments of choice in second line non-small cell lung cancer (NSCLC), however they only benefit a fraction of patients, while existing biomarkers such as PD-L1 expression correlate with outcomes, but are not sufficient to guide therapy.

A serum-based test, BDX008, utilizing mass spectrometry was developed to assist in treatment selection for melanoma patients being considered for nivolumab. The possible role of BDX008 in NSCLC patients treated with nivolumab was evaluated and additionally, the role of the commercially available VeriStrat test, known to have prognostic and predictive roles in NSCLC2, was investigated in nivolumab-treated patients for the first time.

Scientists at the National Institute for Cancer Research (Genova, Italy) collaborating with those at Biodesix, Inc (Boulder, CO, USA) enrolled previously treated patients with advanced NSCLC (both squamous and non-squamous histology) in a single-institution translational study. Patients in the study were treated with nivolumab, an anti-PD-1 agent, and serum samples were evaluated using both an investigational test developed for use in melanoma, and with the Biodesix VeriStrat testing.

Spectra were collected from pre-treatment serum samples on matrix-assisted laser desorption/ionization (MALDI) time of flight mass spectrometer using standard VeriStrat acquisition procedures or “deep MALDI” approach for BDX008 testing. The BDX008 test generates a classification of positive (BDX008+, good outcomes) or negative (BDX008-, poor outcomes); VeriStrat classifies samples as VeriStrat Good (VS Good) or VeriStrat Poor (VS Poor).

The team reported that no correlations were found between objective response or disease control rates and BDX008 or VeriStrat tests by any of the response definition. Early death (ED), defined as death before the first radiological assessment, during 1-4 cycles, occurred in 10 patients (26.3%) classified as BDX008- versusone patient (4.6%) classified as BDX008+. By VeriStrat, ED occurred in two patients (5.4%) classified as VS Good and nine patients (39.1%) classified as VS Poor.

David Brunel, Chief Executive Officer of Biodesix, said, “Our testing methodology, which measures hundreds of proteins in a single assay and then utilizes the machine learning intelligence of our Diagnostic Cortex is uniquely suited to characterizing different immune states and tumor immune escape strategies over time, with the goal of enabling physicians to provide advanced precision medicine.” The study was presented at the 17th World Conference on Lung Cancer, hosted by the International Association for the Study of Lung Cancer held December 4-7, 2016, in Vienna, Austria.

Related Links:
National Institute for Cancer Research
Biodesix
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Multi-Function Pipetting Platform
apricot PP5
New
Uric Acid and Blood Glucose Meter
URIT-10

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.